Human papillomavirus-related squamous cell carcinoma

This study is testing whether giving the HPV vaccine (Gardasil 9) on a different schedule still works well in healthy 9-11 year olds. The standard schedule uses two or three doses, but this study gives a first dose and then a booster later. Researchers will measure antibody level…

This study tests an experimental HPV vaccine in 1,800 females aged 9 to 35. The goal is to see if giving two doses to girls aged 9-14 works as well as three doses in older girls and women. Participants receive the vaccine in their upper arm and have several visits to check their …

This phase 2 trial tests whether giving the HPV vaccine (Gardasil 9) to adults before a kidney transplant helps their immune system fight HPV after transplant, when they must take drugs that weaken immunity. About 51 participants will receive the vaccine before surgery, and resea…

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This early-stage trial tests a new drug called IBRX-042 in 12 people with HPV-related cancers that have come back or worsened. The main goal is to find the safest dose and understand side effects. Participants get three injections, one every three weeks, and are closely monitored…

This study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and s…

This phase 2 trial tests whether adding an experimental vaccine (PRGN-2009) to standard chemotherapy can improve outcomes for people with newly diagnosed HPV-related throat cancer, potentially allowing them to skip radiation. About 70 adults will receive either chemo alone or che…

This study tests a less intense version of standard chemo-radiation for people with HPV-positive throat cancer who have had robotic surgery to remove visible tumors. The goal is to see if the milder treatment works just as well as the standard dose but causes fewer side effects. …

This phase III trial tests whether adding the immunotherapy drug nivolumab after standard chemotherapy and radiation helps people with HPV-positive throat cancer live longer without the cancer growing. About 636 patients with intermediate-risk, locally advanced disease will eithe…

This study compares a reduced dose of radiation therapy combined with the immunotherapy drug nivolumab against the standard treatment of full-dose radiation plus cisplatin for early-stage HPV-positive oropharyngeal cancer in non-smokers. About 384 participants are enrolled to see…

This study is testing whether a PET scan taken partway through radiation treatment can identify patients with HPV-related throat cancer who can safely receive a lower dose of radiation. The goal is to reduce side effects while still controlling the cancer. About 120 adults with s…

This pilot study tests a personalized radiation plan for people with HPV-related throat cancer that is considered high-risk. Using advanced scans (MRI and PET), doctors adjust the radiation dose to target the most aggressive parts of the tumor. The goal is to see if this approach…

This study looks at whether giving a shorter course of lower-dose radiation after robotic surgery is safe for people with HPV-related throat cancer. About 104 adults with early-stage disease will receive this de-intensified treatment. The goal is to keep the cancer from coming ba…

This study tests whether a vaccine (PDS0101) given alone or with an immunotherapy drug (pembrolizumab) can shrink HPV-related throat tumors before surgery. About 20 adults with advanced cancer that has spread to nearby lymph nodes will receive the treatment. The goal is to see if…

This study tests whether a much lower dose of radiation (30 Gy) combined with standard chemotherapy works as well as the usual high dose (70 Gy) for people with HPV-positive throat cancer. The goal is to reduce long-term side effects while still controlling the cancer. About 316 …

This study compares a lower dose of radiation to the standard dose for people with HPV-positive throat cancer. The goal is to see if the lower dose can control the cancer just as well while causing fewer side effects. The trial involves 23 participants with advanced but non-sprea…

This early-phase trial tests whether immune cells from a vaccinated relative can help treat advanced HPV16-related cancers. Up to 24 patients will receive either a bone marrow transplant or a special infusion of donor immune cells. The main goals are to check safety and find the …

This study looks at whether giving a lower dose of radiation after robotic surgery can help people with HPV-positive throat cancer have fewer side effects, like trouble swallowing, while still controlling the cancer. About 33 adults with this type of cancer will receive the reduc…

This early-phase trial tests an HPV vaccine series in healthy relatives of patients with advanced HPV-related cancer. The goal is to generate HPV-specific white blood cells that can be collected and used in a bone marrow transplant or donor lymphocyte infusion for the patient. Th…

This study tests a combination of two drugs—TG4001 (a biologic that targets HPV) and avelumab (an immunotherapy)—in people with advanced HPV-16 cancers that cannot be removed by surgery or cured by radiation. The trial has two phases: first, to find a safe dose, and second, to se…

This study compares two standard treatments—radiation therapy and surgery—for people with HPV-related throat cancer. The goal is to see which approach provides better survival and quality of life. About 61 adults with early-stage cancer are taking part to help guide future treatm…

This study tests whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help control locally advanced head and neck cancer. About 45 adults with this cancer will receive the drug combination. The main goal is to see if this approach imp…

This early-phase study tests HB-200 (a combination of two investigational drugs) in 7 people with HPV16-positive head and neck cancer who have completed standard treatment but still show signs of HPV DNA in their blood. The goal is to see if HB-200 can target and eliminate any re…

This early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…

This study is testing whether a blood test called NavDx can find HPV-related oropharyngeal cancer early by looking for HPV DNA in the blood. Researchers are enrolling adults aged 45 and older with multiple sexual partners who have no history of this cancer. Participants give bloo…

This trial tests whether a game-based mobile app can increase HPV vaccination among young cancer survivors. Participants use the app to learn about HPV risks and get reminders to complete the vaccine series. The study includes survivors aged 18-26 and caregivers of younger surviv…

This study follows women who previously received either one or two doses of the Gardasil9 HPV vaccine to see how long protection against HPV infection lasts. Researchers will check for persistent infections with HPV types linked to cancer. The goal is to understand if fewer doses…

This trial tests whether a program that combines educational materials with electronic health record reminders can increase HPV vaccination rates among children and young adults aged 11–26 in four Appalachian states. The goal is to improve vaccine uptake and ultimately prevent ce…

This study looks at whether women in rural Uganda can screen themselves for cervical cancer using a simple HPV test at home. Over 2,500 women aged 25-49 will collect their own samples during community health campaigns. The goal is to see if this approach increases screening rates…

This study is testing whether giving less radiation to the lymph nodes can reduce side effects for people with low-risk HPV-related throat cancer. The goal is to see if doctors can safely skip radiation to some lymph node areas without increasing the chance of the cancer coming b…

This study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections fr…

This completed study examined 217 Hispanic people living with HIV in California, Mexico, and Puerto Rico to see if the types of bacteria in the anus are linked to high-risk HPV infection and pre-cancerous lesions. Researchers collected anal swabs and questionnaires to compare mic…

This study is checking how long the HPV vaccine protects women who received one, two, or three doses. Researchers are following about 946 women from an earlier trial in Costa Rica for up to 20 years after their shots. By testing blood samples, they hope to learn if one dose might…

This study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit fr…

This study checks how long protection from a single HPV vaccine booster lasts in children who got the shot at age 9-11. Researchers will measure antibody levels in blood samples taken up to 6 years after the first dose. The goal is to understand if one booster provides lasting im…